The three pathways of advanced glycation end product synthesis: Hodge, Namiki, and Wolff - a clinically oriented mechanistic synthesis with network-based implications.

Background: Advanced Glycation End Products (AGEs) accumulate under chronic hyperglycemia and contribute to type 2 diabetes mellitus (T2DM) complications. Three chemical routes generate AGEs Objective: This paper provides a clinically oriented mechanistic synthesis of the three pathways, identifying their points of convergence and divergence, and proposes - as a hypothesis-generating organizing schema rather than as established biology - a clinical biomarker mapping linking each pathway to routinely accessible laboratory parameters as a basis for prospective validation. Approach: Narrative mechanistic review synthesizing primary biochemistry, dicarbonyl chemistry, and clinical biomarker literatures. Findings: The three pathways converge upon a shared reactive dicarbonyl pool comprising methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG); upon the GLO1/GLO2 glyoxalase axis (highest catalytic efficiency for MGO; complementary handling of 3-DG by aldose/aldo-keto reductases); and upon RAGE-mediated inflammatory amplification. They diverge in their dominant kinetic drivers (sustained hyperglycemia for Hodge; glycemic variability for Namiki; oxidative-metal milieu for Wolff) and characteristic AGE adducts. Methylglyoxal also arises substantially from glycolytic triose phosphate degradation independent of the AGE synthesis pathways. We propose that routine laboratory parameters - HbA1c × diabetes duration, glycemic variability indices, hs-CRP, ferritin, gamma-glutamyl transferase, and red cell distribution width - may serve as accessible clinical proxies for pathway-specific activity, with the caveat that these mappings require prospective validation. Conclusions: The Hodge, Namiki, and Wolff pathways are best understood as an integrated AGE synthesis network. This has implications for therapeutic strategy, favoring approaches that act on shared downstream mediators rather than single-pathway interventions, and for the design of pathway-resolved clinical biomarker panels. The proposed mappings and temporal staging are presented as testable hypotheses, not as established clinical algorithms; their validation will require prospective biomarker studies in defined T2DM cohorts.